Legal Opinion
Takeda Pharmaceuticals U.S.A., Inc. v. Burwell
Court of Appeals for the D.C. Circuit
Decided July 15, 2016No. 15-5021 Consolidated with 15-5022PublishedCited by 2 opinions
1Opinion of the Court
JUDGMENT
2Per curiam
This appeal was considered on the record from the United States District Court for the District of Columbia and on the briefs and oral arguments of the parties. The Court has afforded the issues full consideration and has determined that they do not warrant a published opinion. See D.C. Cir. R. 36(d). It is
ORDERED and ADJUDGED that the portion of the appeal seeking review of FDA’s decision to approve Mitigare without Hikma’s certifying to the Colcrys patents be DISMISSED AS MOOT and that .this portion of the judgment of the District Court be VACATED. It is
FURTHER ORDERED and ADJUDGED…
3Cases cited4 opinions
- Baltimore Gas & Electric Co. v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 1983
- Pharmachemie B.V. v. Barr Laboratories, Inc.Court of Appeals for the D.C. Circuit · 2002
- Takeda Pharmaceuticals, U.S.A., Inc. v. BurwellDistrict Court, District of Columbia · 2015
- Takeda Pharmaceuticals U.S.A., Inc. v. West-Ward Pharmaceutical Corp.District Court, D. Delaware · 2016
4Cited by2 opinions
- Jazz Pharmaceuticals, Inc. v. BecerraDistrict Court, District of Columbia · 2024
- Norwich Pharmaceuticals, Inc. v. BecerraDistrict Court, District of Columbia · 2025